New Delhi: Through a recent notification, Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals and National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices/retail prices of 58 formulations exclusive of goods and services tax (GST).
While NPPA has fixed retail prices of 56 formulations, it has also capped the ceiling prices of two formulations.
The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.
These include a number of life-saving combinations of anti-hypertensives, anti-diabetics, lipid-lowering agents, antibiotics, diuretics, antimalarial drugs and haemotanics like Rosuvastatin +Clopidogrel Capsule (Crevast CV 20), Amoxycillin +Clavulante Dry Syrup (Clanoxy Forte), Hydroxychloroquine Sulphate Tablet (OXCQ 300mg), Telmisartan + Chlorthalidone Tablet (Telpha-CH), Brimonidine + Timolol Eye Drops (New Albrim LST), Ferrous Ascorbate +Folic Acid Tablet, Cefixime + Ofloxacin Tablet (Ranixime Plus), Furosemide, etc.
The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.
It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.
To check out the details click on the links given below
Medical Dialogues had earlier reported that NPPA has fixed the retail and ceiling prices of 22 formulations used for the treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.